Abstract：
UNASSIGNED: Glioblastoma (GBM) is an extremely aggressive form of brain tumor with low survival rates. Current treatments such as chemotherapy, radiation, and surgery are problematic due to tumor growth, invasion, and tumor microenvironment. GBM cells are resistant to these standard treatments, and the heterogeneity of the tumor makes it difficult to find a universal approach. Progression of GBM and acquisition of resistance to therapy are due to the complex interplay between tumor cells and the TME. A significant portion of the TME consists of an inflammatory infiltrate, with microglia and macrophages being the predominant cells.
UNASSIGNED: Analysis of the literature data over a course of 5 years suggest that the tumor-associated macrophages (TAMs) are capable of releasing cytokines and growth factors that promote tumor proliferation, survival, and metastasis while inhibiting immune cell function at the same time.
UNASSIGNED: Thus, immunosuppressive state, provided with this intensively studied kind of TME cells, is supposed to promote GBM development through TAMs modulation of tumor treatment-resistance and aggressiveness. Therefore, TAMs are an attractive therapeutic target in the treatment of glioblastoma.
UNASSIGNED: This review provides a comprehensive overview of the latest research on the nature of TAMs and the development of therapeutic strategies targeting TAMs, focusing on the variety of macrophage properties, being modulated, as well as molecular targets.
UNASSIGNED: Analysis of the literature data over a course of 5 years suggest that the tumor-associated macrophages (TAMs) are capable of releasing cytokines and growth factors that promote tumor proliferation, survival, and metastasis while inhibiting immune cell function at the same time.
UNASSIGNED: Thus, immunosuppressive state, provided with this intensively studied kind of TME cells, is supposed to promote GBM development through TAMs modulation of tumor treatment-resistance and aggressiveness. Therefore, TAMs are an attractive therapeutic target in the treatment of glioblastoma.
UNASSIGNED: This review provides a comprehensive overview of the latest research on the nature of TAMs and the development of therapeutic strategies targeting TAMs, focusing on the variety of macrophage properties, being modulated, as well as molecular targets.
摘要：
■胶质母细胞瘤（GBM）是一种极具侵袭性的脑肿瘤，生存率低。目前的治疗方法，如化疗，辐射,由于肿瘤生长，手术是有问题的，入侵,和肿瘤微环境。GBM细胞对这些标准治疗有抵抗力，而肿瘤的异质性使得很难找到一种通用的办法。GBM的进展和对治疗的抗性的获得是由于肿瘤细胞和TME之间复杂的相互作用。TME的很大一部分由炎症浸润组成，小胶质细胞和巨噬细胞是主要细胞。
■对5年的文献数据的分析表明，肿瘤相关巨噬细胞（TAMs）能够释放促进肿瘤增殖的细胞因子和生长因子，生存,和转移，同时抑制免疫细胞功能。
■因此，免疫抑制状态，提供这种深入研究的TME细胞，应该通过TAMs调节肿瘤治疗抗性和侵袭性来促进GBM的发展。因此,TAM是治疗胶质母细胞瘤的一个有吸引力的治疗靶点。
■这篇综述全面概述了有关TAM性质的最新研究以及针对TAM的治疗策略的发展，专注于巨噬细胞特性的多样性，被调制，以及分子靶标。
■对5年的文献数据的分析表明，肿瘤相关巨噬细胞（TAMs）能够释放促进肿瘤增殖的细胞因子和生长因子，生存,和转移，同时抑制免疫细胞功能。
■因此，免疫抑制状态，提供这种深入研究的TME细胞，应该通过TAMs调节肿瘤治疗抗性和侵袭性来促进GBM的发展。因此,TAM是治疗胶质母细胞瘤的一个有吸引力的治疗靶点。
■这篇综述全面概述了有关TAM性质的最新研究以及针对TAM的治疗策略的发展，专注于巨噬细胞特性的多样性，被调制，以及分子靶标。
